Nanobiotix ADR(NBTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:00 PM ET (Korea 11/3 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.27 | Insider Own | 18.09% | Shs Outstand | 50.8M | Perf Week | -10.85% |
| Market Cap | 1.43B | Forward P/E | - | EPS next Y | 63.86% | Insider Trans | - | Shs Float | 41.7M | Perf Month | 9.17% |
| Enterprise Value | 1.43B | PEG | - | EPS next Q | - | Inst Own | 0.33% | Short Float | 0.47% | Perf Quarter | -28.87% |
| Income | -0.06B | P/S | 146.89 | EPS this Y | -5.1% | Inst Trans | 4.64% | Short Ratio | 1.32 | Perf Half Y | -9.79% |
| Sales | 0.01B | P/B | - | EPS next 5Y | - | ROA | -61.74% | Short Interest | 0.20M | Perf YTD | 21.58% |
| Book/sh | -0.75 | P/C | 11.3 | EPS past 3/5Y | 30.98% 18.47% | ROE | - | 52W High | -50.81% ($57.14) | Perf Year | 34.69% |
| Cash/sh | 2.49 | P/FCF | - | Sales past 3/5Y | - 257.86% | ROIC | -131.02% | 52W Low | 61.37% ($17.42) | Perf 3Y | 426.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -58.83% | Gross Margin | - | Volatility(W/M) | 5.75% 6.46% | Perf 5Y | 158.72% |
| Dividend TTM | - | EV/Sales | 146.39 | Sales Y/Y TTM | - | Oper. Margin | -392.06% | ATR (14) | 2.31 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.44 | EPS Q/Q | -559.84% | Profit Margin | -632.55% | RSI (14) | 46.96 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.44 | Sales Q/Q | -84.39% | SMA20 | 6.27% ($26.45) | Beta | 0.89 | Target Price | $55.66 |
| Payout | - | Debt/Eq | - | Earnings | 2026/9/24 | SMA50 | -12.75% ($32.22) | Rel Volume | 0.8 | Prev Close | $31.37 |
| Employees | 97 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -17.03% ($33.88) | Avg Volume(3M) | 0.15M | Price | $28.11 |
| IPO | 2020/12/11 | Option/Short | Yes/Yes | Trades | 970 | Volume | 119,207 | Change | -10.39% |
A clinical-stage biotech company developing nanotechnology-based cancer therapies. It develops nanoparticle-based drug candidates designed to enhance the effectiveness of radiation therapy, targeting a broad range of solid tumors, and has a lead candidate in late-stage clinical development. The company is pursuing entry into the oncology market through a differentiated nano-medicine approach that combines with radiation therapy.
Over the past 1 year, roughly in the middle
51% below its 1-year high.
Traded about as much as usual. That is 80% of its average volume.
NBTX has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -5.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $14,689. Peers typically go for $1,231.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +158.7%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
TINY ProShares Nanotechnology ETF 0.03% 
FPXE First Trust IPOX (R) Europe Equity Opportunities ETF <0.01% 
ISCF iShares International Small-Cap Equity Factor ETF <0.01% 
IEUS iShares MSCI Europe Small-Cap ETF <0.01% 
GWX State Street SPDR S&P International Small Cap ETF <0.01% It ranks #130 of 597 in the industry
Based on market cap of $1B.
FAQ
What kind of company is NBTX?
NBTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NBTX?
The market cap of NBTX is approximately $1.4B, ranking 2,315 within its sector.
What is the 52-week high and low for NBTX?
NBTX has recorded a 52-week high of $57.14 and a low of $17.42.
